What Was Approved?
On August 6, 2026, the U.S. Food and Drug Administration granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for certain adults with advanced melanoma.
The approval applies to adults with:
- Unresectable advanced cutaneous melanoma
- Disease progression after a treatment regimen containing a programmed death receptor-1, or PD-1, blocking antibody
Tudriqev is not approved as a general treatment for every patient with melanoma.
What Is Tudriqev?
Tudriqev is a genetically modified oncolytic viral therapy.
It is designed to be injected directly into melanoma tumors.
The treatment is used together with nivolumab, an immune checkpoint inhibitor.
How Does an Oncolytic Viral Therapy Work?
Oncolytic viral therapies use modified viruses designed to infect and damage cancer cells.
Tudriqev is administered directly into tumors, where the modified virus is intended to replicate within tumor tissue and contribute to destruction of cancer cells.
The treatment may also stimulate immune activity against the tumor.
Its exact clinical effects can vary among patients.
How Is Tudriqev Given?
Tudriqev is given by intratumoral injection, meaning it is injected directly into selected tumors.
According to the FDA-approved prescribing information, the dose is based on the size of the treated lesions.
The recommended volume is 1 mL for each centimeter of the largest tumor dimension, with a maximum of 10 mL across all lesions treated during a single dose.
The injections are generally given every two weeks for the initial treatment series.
Nivolumab is administered intravenously according to its own prescribing information.
Why Was Tudriqev Granted Accelerated Approval?
The FDA used the accelerated approval pathway.
This approval was based on:
- Objective response rate
- Duration of response
These measures showed antitumor activity that the FDA determined could support accelerated approval in this setting.
Continued approval may depend on confirmation of clinical benefit in additional studies.
What Did the Clinical Study Show?
According to the FDA, approximately one in four patients responded to the combination treatment.
Among patients who responded, the median duration of response was nearly 14 months.
These results describe outcomes observed in the clinical study and do not guarantee that an individual patient will respond.
Does Accelerated Approval Mean the Benefit Is Fully Confirmed?
Not yet.
The FDA specifically states that continued approval may be contingent on verification of clinical benefit in confirmatory trials.
A phase 3 confirmatory study is required to further evaluate the treatment’s safety and effectiveness.
For that reason, it is important not to interpret accelerated approval as proof of a definitive overall survival benefit.
What Are the Common Side Effects?
According to the FDA-approved prescribing information, common non-laboratory adverse reactions occurring in at least 10% of patients included:
- Fatigue
- Fever
- Infections
- Chills
- Musculoskeletal pain
- Nausea
- Diarrhea
- Injection-site reactions
- Headache
- Cough
- Flu-like symptoms
- Rash
- Vomiting
- Itching
- Joint pain
- Decreased appetite
- Dizziness
- Shortness of breath
- Swelling
- Abdominal pain
Other adverse effects can also occur.
What Are the Important Safety Warnings?
The prescribing information includes several important warnings and precautions.
Visceral Injury
Because Tudriqev is injected directly into tumors, there is a risk of injury to nearby organs or tissues during treatment.
Healthcare professionals should carefully select injectable lesions and monitor patients during and after administration.
Immune-Mediated Reactions
Tudriqev is used with nivolumab, and immune-mediated adverse reactions can occur.
Reported immune-related events have included conditions affecting organs such as the:
- Colon
- Liver
- Heart
- Nervous system
- Skin
Patients should promptly report new or worsening symptoms to their oncology team.
Are Antiviral Medicines a Concern?
Yes.
The FDA prescribing information notes that antiviral medications may reduce the effectiveness of Tudriqev.
The label recommends delaying Tudriqev administration for 72 hours after antiviral treatment.
Patients should tell their oncology team about all prescription medicines, over-the-counter medicines, and supplements they use.
Are There Pregnancy Considerations?
Yes.
The prescribing information recommends effective contraception during treatment and for 90 days after the final Tudriqev dose for patients of reproductive potential and for certain male patients with partners who could become pregnant.
Individual recommendations should be reviewed with the oncology team.
Why Is This Approval Important?
Advanced melanoma that continues to progress after PD-1-based treatment can be difficult to treat.
Tudriqev provides a new treatment approach by combining an intratumoral oncolytic viral therapy with nivolumab for a specifically defined group of previously treated patients.
Bottom Line
Tudriqev (vusolimogene oderparepvec-wtpg) is a newly FDA-approved genetically modified oncolytic viral therapy used with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed after PD-1-blocking therapy.
The approval was granted through the accelerated approval pathway based on tumor response and duration of response.
Because continued approval may depend on confirmatory evidence and the treatment can cause significant adverse effects, it should be administered and monitored by an oncology team experienced with advanced melanoma and intratumoral therapies.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma, August 6, 2026.
- U.S. Food and Drug Administration (FDA) — FDA Grants Accelerated Approval to Vusolimogene Oderparepvec-wtpg in Combination With Nivolumab for Melanoma, August 6, 2026.
- U.S. Food and Drug Administration (FDA) — Tudriqev Prescribing Information, revised August 2026.
- U.S. Food and Drug Administration (FDA) — Tudriqev Product Information and Approval Documents.